Ebola Pharmaceutical Drug Companies and Drug Companies

Search results

- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock...
  Digital Journal· 2 weeks ago
  (NYSE Amer:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that the Phase... Clinical Trial of NV-387 is completed successfully & ...
- RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
  NBC 17 Raleigh· 5 days ago
  TEL-AVIV, Israel and RALEIGH, N.C., May 6, 2024 /PRNewswire...Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical ...
- NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York...
  Digital Journal· 13 hours ago
  (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company' ...